...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of psychopharmacology >Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up
【24h】

Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up

机译：利培酮长效注射剂治疗多巴胺超敏性精神病的难治性精神分裂症：一项为期2年的前瞻性研究结果，包括另外的1年随访

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Dopamine supersensitivity psychosis (DSP) resulting from antipsychotic treatment is related to treatment-resistant schizophrenia (TRS), and its treatment has not been established to date. Maintaining thoroughly stable occupancy of the dopamine D2 receptor by risperidone long-acting injectable (RLAI) is one strategy for treatment. In this study, RLAI was given as an adjunctive medication to oral antipsychotic(s), which were switched partially and gradually to RLAI in 108 treatment-resistant patients for an additional 1-year follow-up in a 2-year study, and to compare the effects in 72 patients with a DSP history (DSP group) and 36 patients without this history (NonDSP group). Although both groups showed significant improvements in the total Brief Psychotic Rating Scale (BPRS) score during the follow-up period, greater improvement was observed for the DSP group than the NonDSP group. High doses (> 850 mg chlorpromazine-dose combined of oral antipsychotics and RLAI) did not significantly change in both groups throughout the study period; however, extrapyramidal symptoms, including tardive dyskinesia, were significantly improved only in the patients with DSP. This study strongly suggested that the RLAI treatment, even with only partial switching, provides relief from refractory symptoms, particularly for patients with a history of DSP.
机译：抗精神病药物治疗引起的多巴胺超敏性精神病（DSP）与耐药性精神分裂症（TRS）有关，迄今为止尚未确定其治疗方法。利培酮长效注射剂（RLAI）维持多巴胺D2受体的完全稳定占用是一种治疗策略。在这项研究中，将RLAI用作口服抗精神病药的辅助药物，在2年的研究中，对108例抗药性患者进行了部分逐步地改用RLAI，并进行了1年的随访。比较72位有DSP病史的患者（DSP组）和36位无此病史的患者（NonDSP组）的疗效。尽管两组在随访期间的总简短精神病评定量表（BPRS）得分均显着改善，但与非NonDSP组相比，DSP组观察到了更大的改善。在整个研究期间，两组的高剂量（大于850毫克氯丙嗪-口服抗精神病药和RLAI的总剂量）均无显着变化。但是，锥体束外症状，包括迟发性运动障碍，仅在患有DSP的患者中得到明显改善。这项研究强烈建议，即使仅进行部分切换，RLAI治疗也可以缓解难治性症状，特别是对于有DSP病史的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号